

# ACT Onco<sup>®</sup> + Report

PATIENT		
Name: 李任浩		Patient ID: 46371113
Date of Birth: Dec 14, 1993		Gender: Male
Diagnosis: Ewing sarcoma		
ORDERING PHYSICIAN		
Name: 顏厥全醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11077904	Collection site: Lung	Type: FFPE tissue
Date received: Mar 17, 2022	Lab ID: AA-22-01315	D/ID: NA

## ABOUT ACT Onco<sup>®</sup>+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) ( $\leq 15$  nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 31 genes.

## SUMMARY FOR ACTIONABLE VARIANTS

### VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

### VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
	Not detected	

#### Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

# ACTOnco<sup>®</sup> + Report

## TESTING RESULTS

### VARIANT(S) WITH CLINICAL RELEVANCE

#### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
Not detected		

#### - Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr10	PTEN	Heterozygous deletion	1
Chr9	CDKN2A	Heterozygous deletion	1

#### - Fusions

Fusion Gene & Exon	Transcript ID
Not tested	

#### - Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	1.2 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

#### Note:

- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 70% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco<sup>®</sup>+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at  $\geq 7.5$  mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is  $< 30\%$ .

# ACT Onco<sup>®</sup> + Report

## THERAPEUTIC IMPLICATIONS

### TARGETED THERAPIES

Not Applicable.

### IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

#### - Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

### CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

### HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

## OTHERS

### Pharmacogenomic implication

Gene	Detection Site	Genotype	Drug Impact	Level of Evidence*
UGT1A1	rs4148323	AG	Irinotecan-based regimens	Level 1B

#### Clinical Interpretation:

Patients with the AG genotype and cancer who are treated with irinotecan-based regimens may have an increased risk of diarrhea and neutropenia as compared to patients with the GG genotype, or a decreased risk of diarrhea and neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of diarrhea and neutropenia.

\* Level of evidence was defined by PharmGKB (<https://www.pharmgkb.org/page/clinAnnLevels>)

**Level 1A:** Clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation.

**Level 1B:** Clinical annotations describe variant-drug combinations with a high level of evidence supporting the association but no variant-specific prescribing guidance in an annotated clinical guideline or FDA drug label.

**Level 2A:** Variants in Level 2A clinical annotations are found in PharmGKB's Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely.

#### Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

# ACT Onco<sup>®</sup> + Report

## VARIANT INTERPRETATION

### CDKN2A Heterozygous deletion

#### Biological Impact

The Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) gene encodes the p16 (p16INK4a) and p14 (ARF) proteins. p16INK4a binds to CDK4 and CDK6, inhibiting these CDKs from binding D-type cyclins and phosphorylating the retinoblastoma (RB) protein whereas p14 (ARF) blocks the oncogenic activity of MDM2 by inhibiting MDM2-induced degradation of p53<sup>[1][2][3]</sup>. CDKN2A has been reported as a haploinsufficient tumor suppressor with one copy loss that may lead to weak protein expression and is insufficient to execute its original physiological functions<sup>[4]</sup>. Loss of CDKN2A has been frequently found in human tumors that result in uncontrolled cell proliferation<sup>[5][6]</sup>.

#### Therapeutic and prognostic relevance

Intact p16-Cdk4-Rb axis is known to be associated with sensitivity to cyclin-dependent kinase inhibitors<sup>[7][8]</sup>. Several case reports also revealed that patients with CDKN2A-deleted tumors respond to the CDK4/6-specific inhibitor treatments<sup>[9][10][11]</sup>. However, there are clinical studies that demonstrated CDKN2A nuclear expression, CDKN2A/CDKN2B co-deletion, or CDKN2A inactivating mutation was not associated with clinical benefit from CDK4/6 inhibitors, such as palbociclib and ribociclib, in RB-positive patients<sup>[12][13][14]</sup>. However, CDKN2A loss or mutation has been determined as an inclusion criterion for the trial evaluating CDK4/6 inhibitors efficacy in different types of solid tumors (NCT02693535, NCT02187783).

Notably, the addition of several CDK4/6 inhibitors to hormone therapies, including palbociclib in combination with letrozole, ribociclib plus letrozole, and abemaciclib combines with fulvestrant, have been approved by the U.S. FDA for the treatment of ER+ and HER2- breast cancer<sup>[8][15][16]</sup>.

In a Phase I trial, a KRAS wild-type squamous non-small cell lung cancer (NSCLC) patient with CDKN2A loss had a partial response when treated with CDK4/6 inhibitor abemaciclib<sup>[10]</sup>. Administration of combined palbociclib and MEK inhibitor PD-0325901 yield promising progression-free survival among patients with KRAS mutant non-small cell lung cancer (NSCLC) (AACR 2017, Abstract CT046). Moreover, MEK inhibitor in combination with CDK4/6 inhibitor demonstrates significant anti-KRAS-mutant NSCLC activity and radiosensitizing effect in preclinical models<sup>[17]</sup>.

A retrospective analysis demonstrated that concurrent deletion of CDKN2A with EGFR mutation in patients with non-small cell lung cancer (NSCLC), predicts worse overall survival after EGFR-TKI treatment<sup>[18]</sup>.

### PTEN Heterozygous deletion

#### Biological Impact

The phosphatase and tensin homolog deleted on chromosome ten (PTEN) gene encodes a lipid/protein phosphatase that is important for the regulation of cell proliferation, survival, homologous recombination and maintenance of genomic integrity<sup>[19][20]</sup>. PTEN acts as an essential tumor suppressor by antagonizing the PI3K/AKT/mTOR signaling pathway<sup>[21]</sup>. PTEN is a haploinsufficient tumor suppressor gene, in which having only one copy of the wild-type allele does not produce enough protein product to execute wild-type functions<sup>[22][23][24]</sup>. Germline loss-of-function PTEN mutations are found in approximately 80% of patients with Cowden syndrome, a disorder that is associated with high-penetrance breast and thyroid cancer<sup>[25][26][27]</sup>. Somatic mutations or monoallelic loss of PTEN is regularly observed in a significant fraction of human cancers, including sporadic breast cancer, colon cancer, endometrial cancer, prostate cancer, and glioblastoma<sup>[28][29][30][31][32]</sup>.

#### Therapeutic and prognostic relevance

Somatic loss of PTEN results in aberrant activation of PI3K/AKT/mTOR signaling pathway and provides a mechanistic rationale for PI3K pathway inhibitors treatment<sup>[33][34]</sup>. Preclinical studies demonstrated that PTEN deficiency was associated with increased sensitivity to PI3K pathway inhibitors in selected cancer subtypes<sup>[35][36][37][38][39][40]</sup>. Moreover,

# ACT Onco<sup>®</sup> + Report

early clinical data also indicated that PTEN loss was associated with improved response and longer PFS in patients with advanced breast cancer<sup>[41]</sup>, advanced pancreatic neuroendocrine tumors<sup>[42]</sup>, and metastatic castration-resistant prostate cancer treated with mTORC1 inhibitor, everolimus<sup>[43]</sup>.

Several groups found that PTEN loss was generally associated with poor response to trastuzumab therapy, whether this agent was administered in the neoadjuvant, adjuvant, or metastatic settings<sup>[44][45][46][47][48]</sup>.

Loss of PTEN expression in advanced colorectal cancer (CRC) has been linked with resistance to anti-EGFR mAbs like cetuximab and panitumumab<sup>[49][50][51][52][53][54]</sup>. However, encouraging anti-tumor activity of the combination of an EGFR antibody and a mTORC1 inhibitor (everolimus or temsirolimus) have been reported in early-phase clinical studies (J Clin Oncol. 2011;29 (suppl): abstr 3587; J Clin Oncol. 2013;31 (suppl): abstr 608). Ongoing phase I/II studies testing combinations of EGFR antibodies and PI3K/AKT/mTOR pathway inhibitors (e.g., NCT01816984, NCT01252628, NCT01719380) will provide larger numbers of patients to assess the role of PTEN status in therapeutic response.

Preclinical studies showed that loss of PTEN expression in EGFR mutant cells was associated with decreased sensitivity to EGFR TKIs, erlotinib and gefitinib<sup>[55][56]</sup>. Inhibition of the PI3K/AKT/mTOR signal pathway has been shown to be an effective strategy to radiosensitize NSCLC cells harboring the EGFR activating mutation that acquires resistance to both TKIs due to PTEN loss or inactivation mutations<sup>[57]</sup>.

Loss or biallelic inactivation of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapies, including pembrolizumab and nivolumab in melanoma and leiomyosarcoma patients<sup>[58][59][60]</sup>.

PTEN loss of function mutation has been determined as an inclusion criterion for the trial evaluating olaparib efficacy in metastatic biliary tract cancer (NCT04042831); talazoparib efficacy in HER2-negative breast cancer (NCT02401347), and niraparib efficacy in breast cancer (NCT04508803) or any malignancy (except prostate) cancer (NCT03207347). Clinical data also suggested that PTEN deficient cancers may be sensitive to olaparib<sup>[61]</sup>.

# ACT Onco<sup>®</sup> + Report

## US FDA-APPROVED DRUG(S)

### Abemaciclib (VERZENIO)

Abemaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Abemaciclib is developed and marketed by Eli Lilly under the trade name VERZENIO.

### - FDA Approval Summary of Abemaciclib (VERZENIO)

<b>monarchE</b> NCT03155997	<b>Breast cancer</b> (Approved on 2021/10/12)
	<b>HR-positive, HER2-negative</b> Abemaciclib + tamoxifen/aromatase inhibitor vs. Tamoxifen/aromatase inhibitor [IDFS at 36 months(%): 86.1 vs. 79.0]
<b>MONARCH 3</b> <sup>[62]</sup> NCT00246621	<b>Breast cancer</b> (Approved on 2018/02/26)
	<b>HR-positive, HER2-negative</b> Abemaciclib + anastrozole/letrozole vs. Placebo + anastrozole/letrozole [PFS(M): 28.2 vs. 14.8]
<b>MONARCH 2</b> <sup>[16]</sup> NCT02107703	<b>Breast cancer</b> (Approved on 2017/09/28)
	<b>HR-positive, HER2-negative</b> Abemaciclib + fulvestrant vs. Placebo + fulvestrant [PFS(M): 16.4 vs. 9.3]
<b>MONARCH 1</b> <sup>[63]</sup> NCT02102490	<b>Breast cancer</b> (Approved on 2017/09/28)
	<b>HR-positive, HER2-negative</b> Abemaciclib [ORR(%): 19.7 vs. 17.4]

### Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

### - FDA Approval Summary of Everolimus (AFINITOR)

<b>RADIANT-4</b> <sup>[64]</sup> NCT01524783	<b>Lung or gastrointestinal neuroendocrine tumor</b> (Approved on 2016/02/26)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
<b>BOLERO-2</b> <sup>[65]</sup> NCT00863655	<b>Breast cancer</b> (Approved on 2012/07/20)
	<b>ER+/HER2-</b> Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
<b>EXIST-2</b> NCT00790400	<b>Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma</b> (Approved on 2012/04/26)
	- Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
<b>RADIANT-3</b> <sup>[42]</sup> NCT00510068	<b>Pancreatic neuroendocrine tumor</b> (Approved on 2011/05/05)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
<b>EXIST-1</b> <sup>[66]</sup> NCT00789828	<b>Subependymal giant cell astrocytoma</b> (Approved on 2010/10/29)
	- Everolimus vs. Placebo [ORR(%): 35.0]
<b>RECORD-1</b> <sup>[67]</sup> NCT00410124	<b>Renal cell carcinoma</b> (Approved on 2009/05/30)
	- Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]



# ACT Onco<sup>®</sup> + Report

## Niraparib (ZEJULA)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

### - FDA Approval Summary of Niraparib (ZEJULA)

<b>PRIMA</b> NCT02655016	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2020/04/29)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]
<b>QUADRA<sup>[68]</sup></b> NCT02354586	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2019/10/23)
	<b>HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability)</b>
	Niraparib [ORR(%): 24.0, DOR(M): 8.3]
<b>NOVA<sup>[69]</sup></b> NCT01847274	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/03/27)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

## Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

### - FDA Approval Summary of Olaparib (LYNPARZA)

<b>PROfound<sup>[70]</sup></b> NCT02987543	<b>Prostate cancer</b> (Approved on 2020/05/19)
	<b>ATMm, BRCA1m, BRCA2m, BARD1m, BRIP1m, CDK12m, CHEK1m, CHEK2m, FANCLm, PALB2m, RAD51Bm, RAD51Cm, RAD51Dm, RAD54Lm</b>
	Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
<b>PAOLA-1<sup>[71]</sup></b> NCT02477644	<b>Ovarian cancer</b> (Approved on 2020/05/08)
	<b>HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability)</b>
	Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
<b>POLO<sup>[72]</sup></b> NCT02184195	<b>Pancreatic adenocarcinoma</b> (Approved on 2019/12/27)
	<b>Germline BRCA mutation (deleterious/suspected deleterious)</b>
	Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
<b>SOLO-1<sup>[73]</sup></b> NCT01844986	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2018/12/19)
	<b>Germline or somatic BRCA-mutated (gBRCAm or sBRCAm)</b>
	Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
<b>OlympiAD<sup>[74]</sup></b> NCT02000622	<b>Breast cancer</b> (Approved on 2018/02/06)
	<b>Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative</b>
	Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
<b>SOLO-2/ENGOT-Ov21<sup>[75]</sup></b> NCT01874353	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/08/17)
	<b>gBRCA+</b>
	Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]

# ACT Onco<sup>®</sup> + Report

<b>Study19<sup>[76]</sup></b> NCT00753545	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/08/17)
	-
	Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]
<b>Study 42<sup>[77]</sup></b> NCT01078662	<b>Ovarian cancer</b> (Approved on 2014/12/19)
	<b>Germline BRCA mutation (deleterious/suspected deleterious)</b>
	Olaparib [ORR(%): 34.0, DOR(M): 7.9]

## Palbociclib (IBRANCE)

Palbociclib is an oral, cyclin-dependent kinase (CDK) inhibitor specifically targeting CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Palbociclib is developed and marketed by Pfizer under the trade name IBRANCE.

### - FDA Approval Summary of Palbociclib (IBRANCE)

<b>PALOMA-2<sup>[78]</sup></b> NCT01740427	<b>Breast cancer</b> (Approved on 2017/03/31)
	<b>ER+, HER2-</b>
	Palbociclib + letrozole vs. Placebo + letrozole [PFS(M): 24.8 vs. 14.5]
<b>PALOMA-3<sup>[79]</sup></b> NCT01942135	<b>Breast cancer</b> (Approved on 2016/02/19)
	<b>ER+, HER2-</b>
	Palbociclib + fulvestrant vs. Placebo + fulvestrant [PFS(M): 9.5 vs. 4.6]

## Ribociclib (KISQALI)

Ribociclib is a cyclin-dependent kinase (CDK) inhibitor specifically targeting cyclin D1/CDK4 and cyclin D3/CDK6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Ribociclib is developed by Novartis and Astex Pharmaceuticals and marketed by Novartis under the trade name KISQALI.

### - FDA Approval Summary of Ribociclib (KISQALI)

<b>MONALEESA-2<sup>[15]</sup></b> NCT01958021	<b>Breast cancer</b> (Approved on 2017/03/13)
	<b>HR+, HER2-</b>
	Ribociclib vs. Letrozole [PFS(M): NR vs. 14.7]

## Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

### - FDA Approval Summary of Rucaparib (RUBRACA)

<b>TRITON2</b> NCT02952534	<b>Prostate cancer</b> (Approved on 2020/05/15)
	<b>gBRCA+, sBRCA</b>
	Rucaparib [ORR(%): 44.0, DOR(M): NE]
<b>ARIEL3<sup>[80]</sup></b> NCT01968213	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2018/04/06)
	<b>All HRD tBRCA</b>
	Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]



# ACT Onco<sup>®</sup> + Report

<b>ARIEL2<sup>[81]</sup></b> NCT01482715, NCT01891344	<b>Ovarian cancer</b> (Approved on 2016/12/19)
	<b>Germline and/or somatic BRCA mutation</b>
	Rucaparib [ORR(%): 54.0]

## Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

### - FDA Approval Summary of Talazoparib (TALZENNA)

<b>EMBRACA<sup>[82]</sup></b> NCT01945775	<b>Breast cancer</b> (Approved on 2018/10/16)
	<b>Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative</b>
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

## Temsirolimus (TORISEL)

Temsirolimus is a soluble ester of sirolimus (rapamycin, brand-name drug Rapamune) and functions as an inhibitor of mammalian target of rapamycin complex (mTORC). The inhibitory molecular mechanism is similar to Everolimus. Temsirolimus is developed by Wyeth Pharmaceuticals and marketed by Pfizer under the trade name TORISEL.

### - FDA Approval Summary of Temsirolimus (TORISEL)

<sup>[83]</sup> NCT00065468	<b>Renal cell carcinoma</b> (Approved on 2007/05/30)
	-
	Temsirolimus vs. Ifn- $\alpha$ [OS(M): 10.9 vs. 7.3]

D=day; W=week; M=month

# ACT Onco<sup>®</sup> + Report

## ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

# ACT Onco<sup>®</sup> + Report


## SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
Not Detected							

### - Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



# ACT Onco<sup>®</sup> + Report

## OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ABL2	Splice region	-	c.221-3C>T	NM_007314	-	45.6%	1097
ADGRA2	Splice region	-	c.1833+7G>A	NM_032777	-	54.1%	270
ADGRA2	L474W	10	c.1421T>G	NM_032777	-	50.5%	695
BCL9	M1382V	10	c.4144A>G	NM_004326	COSM4995262	46.9%	422
BRCA1	P346S	10	c.1036C>T	NM_007294	-	50.6%	897
BRCA2	H523R	10	c.1568A>G	NM_000059	COSM9110800	52.6%	1096
CCNH	V120L	4	c.358G>C	NM_001239	-	50.2%	654
CSF1R	Splice region	-	c.1969+4A>T	NM_005211	-	39.8%	596
FGFR3	L575V	13	c.1723C>G	NM_000142	-	52.2%	880
KMT2C	S321N	7	c.962G>A	NM_170606	COSM3304639	7.8%	3999
KMT2D	S23A	2	c.67T>G	NM_003482	-	51.9%	847
MUTYH	A373V	12	c.1118C>T	NM_001128425	-	49.1%	875
ROS1	Y338C	10	c.1013A>G	NM_002944	-	47.3%	1244
SMARCA4	R1135Q	26	c.3404G>A	NM_001128844	COSM1740484	49.1%	687
USH2A	H885Y	13	c.2653C>T	NM_206933	-	47.7%	2755


### Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

# ACT Onco<sup>®</sup> + Report

## TEST DETAILS

### SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Nov 2021
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11077904
- Collection site: Lung
- Examined by: Dr. Yeh-Han Wang
- 1. The percentage of viable tumor cells in total cells in the whole slide (%): 70%
- 2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 70%
- 3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 10%
- 4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 10%
- 5. Additional comment: NA
- Manual macrodissection: Not performed
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

## RUN QC

- Panel: ACTOnco<sup>®</sup>+

### DNA test

- Mean Depth: 930x
- Target Base Coverage at 100x: 93%

# ACT Onco<sup>®</sup> + Report

## LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 31 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

## NEXT-GENERATION SEQUENCING (NGS) METHODS

### DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (Indels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage  $\geq 25$ , allele frequency  $\geq 5\%$  and actionable variants with allele frequency  $\geq 2\%$  were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at  $100\times \geq 85\%$  with a mean coverage  $\geq 500\times$ .

Variants reported in Genome Aggregation database with  $> 1\%$  minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation  $\geq 0.3$  were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco<sup>®</sup> to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to  $\geq 7.5$  mutations per megabase (Muts/Mb); TMB-Low corresponds to  $< 7.5$  Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is  $< 30\%$ .

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in  $> 400$  genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

### RNA test

Extracted RNA was reverse transcribed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen) according to the manufacturer's instructions. Synthesized cDNA was subjected to library construction. Quality and quantity of amplified library were determined using the fragment analyzer (AATI) and Qubit (Invitrogen). Sequencing was performed on the Ion 540<sup>™</sup> Chip / Ion P1<sup>™</sup> Chip and Ion



# ACT Onco<sup>®</sup> + Report

GeneStudio™ S5 Prime System / Ion Proton™ System (Life Technologies). All assays were performed in accordance with ACT Genomics testing SOPs. This test provides total depth  $\geq 20000\times$  with detected RNA process controls  $\geq 6$ .

## DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

## Variant Analysis:

醫藥資訊研究員  
楊杭哲 博士  
Hang-Che Yang Ph.D.



## Sign Off

解剖病理專科醫師王業翰  
Yeh-Han Wang M.D.  
病解字第 000545 號



# ACT Onco<sup>®</sup> + Report

## GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTB	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBK	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC01B1*
SLC01B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

\*Analysis of copy number alterations NOT available.

## FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------


# ACT Onco<sup>®</sup> + Report

## APPENDIX

### POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION


Gene	Therapies	Possible effect
CDKN2A	Abemaciclib, Palbociclib, Ribociclib	<b>sensitive</b>
PTEN	Everolimus, Niraparib, Olaparib, Rucaparib, Talazoparib, Temozolimus	<b>sensitive</b>
PTEN	Cetuximab, Erlotinib, Gefitinib, Panitumumab, Trastuzumab	<b>resistant</b>

### SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS




1: Everolimus, Temozolimus

# ACT Onco<sup>®</sup> + Report



## 1: Abemaciclib, Palbociclib, Ribociclib



## 1: Olaparib, Niraparib, Rucaparib, Talazoparib

# ACT Onco<sup>®</sup> + Report

## DISCLAIMER

### 法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

### 醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

### 基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

### 證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

### 責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

# ACT Onco<sup>®</sup> + Report

## REFERENCE

1. PMID: 17055429; 2006, Cell;127(2):265-75  
The regulation of INK4/ARF in cancer and aging.
2. PMID: 8521522; 1995, Cell;83(6):993-1000  
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
3. PMID: 9529249; 1998, Cell;92(6):725-34  
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
4. PMID: 16115911; 2005, Clin Cancer Res;11(16):5740-7  
Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
5. PMID: 7550353; 1995, Nat Genet;11(2):210-2  
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.
6. PMID: 24089445; 2013, Clin Cancer Res;19(19):5320-8  
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
7. PMID: 27849562; 2017, Gut;66(7):1286-1296  
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
8. PMID: 25524798; 2015, Lancet Oncol;16(1):25-35  
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
9. PMID: 28283584; 2017, Oncologist;22(4):416-421  
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
10. PMID: 27217383; 2016, Cancer Discov;6(7):740-53  
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
11. PMID: 26715889; 2015, Curr Oncol;22(6):e498-501  
Does CDKN2A loss predict palbociclib benefit?
12. PMID: 25501126; 2015, Clin Cancer Res;21(5):995-1001  
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
13. PMID: 27542767; 2016, Clin Cancer Res;22(23):5696-5705  
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
14. PMID: 24797823; 2014, Oncologist;19(6):616-22  
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
15. PMID: 27717303; 2016, N Engl J Med;375(18):1738-1748  
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
16. PMID: 28580882; 2017, J Clin Oncol;35(25):2875-2884  
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
17. PMID: 26728409; 2016, Clin Cancer Res;22(1):122-33  
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
18. PMID: 31401335; 2019, Transl Oncol;12(11):1425-1431



# ACT Onco<sup>®</sup> + Report

Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors.

19. PMID: 17218262; 2007, Cell;128(1):157-70  
Essential role for nuclear PTEN in maintaining chromosomal integrity.
20. PMID: 18794879; 2008, Oncogene;27(41):5443-53  
PTEN: a new guardian of the genome.
21. PMID: 18767981; 2009, Annu Rev Pathol;4():127-50  
PTEN and the PI3-kinase pathway in cancer.
22. PMID: 21125671; 2011, J Pathol;223(2):137-46  
Haplo-insufficiency: a driving force in cancer.
23. PMID: 11553783; 2001, Proc Natl Acad Sci U S A;98(20):11563-8  
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.
24. PMID: 20400965; 2010, Nat Genet;42(5):454-8  
Subtle variations in Pten dose determine cancer susceptibility.
25. PMID: 9467011; 1998, Hum Mol Genet;7(3):507-15  
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.
26. PMID: 24136893; 2013, J Natl Cancer Inst;105(21):1607-16  
Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.
27. PMID: 21430697; 2011, Nat Rev Cancer;11(4):289-301  
PTEN loss in the continuum of common cancers, rare syndromes and mouse models.
28. PMID: 18455982; 2008, Cell;133(3):403-14  
Tenets of PTEN tumor suppression.
29. PMID: 9393738; 1997, Cancer Res;57(23):5221-5  
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
30. PMID: 9829719; 1998, Clin Cancer Res;4(11):2577-83  
Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
31. PMID: 9582022; 1998, Oncogene;16(13):1743-8  
Analysis of PTEN and the 10q23 region in primary prostate carcinomas.
32. PMID: 9671321; 1998, Oncogene;17(1):123-7  
Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas.
33. PMID: 11504908; 2001, Proc Natl Acad Sci U S A;98(18):10314-9  
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
34. PMID: 23714559; 2013, Am Soc Clin Oncol Educ Book;():  
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
35. PMID: 20231295; 2010, J Biol Chem;285(20):14980-9  
Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
36. PMID: 23287563; 2013, Clin Cancer Res;19(7):1760-72  
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
37. PMID: 17047067; 2006, Cancer Res;66(20):10040-7

# ACT Onco<sup>®</sup> + Report

Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.

38. PMID: 22422409; 2012, Clin Cancer Res;18(6):1777-89  
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
39. PMID: 22662154; 2012, PLoS One;7(5):e37431  
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
40. PMID: 23136191; 2012, Clin Cancer Res;18(24):6771-83  
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
41. PMID: 27091708; 2016, J Clin Oncol;34(18):2115-24  
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
42. PMID: 21306238; 2011, N Engl J Med;364(6):514-23  
Everolimus for advanced pancreatic neuroendocrine tumors.
43. PMID: 23582881; 2013, Eur Urol;64(1):150-8  
Phase 2 trial of single-agent everolimus in chemotherapy-naïve patients with castration-resistant prostate cancer (SAKK 08/08).
44. PMID: 15324695; 2004, Cancer Cell;6(2):117-27  
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
45. PMID: 20813970; 2010, Am J Pathol;177(4):1647-56  
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
46. PMID: 21135276; 2011, J Clin Oncol;29(2):166-73  
Loss of phosphatase and tensin homolog or phosphoinositide-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
47. PMID: 21594665; 2011, Breast Cancer Res Treat;128(2):447-56  
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
48. PMID: 17936563; 2007, Cancer Cell;12(4):395-402  
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
49. PMID: 18700047; 2008, BMC Cancer;8():234  
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.
50. PMID: 17940504; 2007, Br J Cancer;97(8):1139-45  
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
51. PMID: 19398573; 2009, J Clin Oncol;27(16):2622-9  
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
52. PMID: 19953097; 2010, Br J Cancer;102(1):162-4  
PTEN status in advanced colorectal cancer treated with cetuximab.
53. PMID: 27605871; 2016, World J Gastroenterol;22(28):6345-61  
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
54. PMID: 24666267; 2014, Acta Oncol;53(7):852-64  
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
55. PMID: 19351834; 2009, Cancer Res;69(8):3256-61

# ACT Onco<sup>®</sup> + Report

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

56. PMID: 23133538; 2012, PLoS One;7(10):e48004  
Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.
57. PMID: 23592446; 2013, J Cell Biochem;114(6):1248-56  
mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
58. PMID: 26645196; 2016, Cancer Discov;6(2):202-16  
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
59. PMID: 28228279; 2017, Immunity;46(2):197-204  
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
60. PMID: 30150660; 2018, Nat Genet;50(9):1271-1281  
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
61. PMID: 21468130; 2011, Nat Rev Clin Oncol;8(5):302-6  
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
62. PMID: 28968163; 2017, J Clin Oncol;35(32):3638-3646  
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
63. PMID: 28533223; 2017, Clin Cancer Res;23(17):5218-5224  
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2-Metastatic Breast Cancer.
64. PMID: 26703889; 2016, Lancet;387(10022):968-977  
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
65. PMID: 22149876; 2012, N Engl J Med;366(6):520-9  
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
66. PMID: 23158522; 2013, Lancet;381(9861):125-32  
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
67. PMID: 18653228; 2008, Lancet;372(9637):449-56  
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
68. PMID: 30948273; 2019, Lancet Oncol;20(5):636-648  
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
69. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164  
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
70. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102  
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
71. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428  
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
72. PMID: 31157963; 2019, N Engl J Med;381(4):317-327  
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
73. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505  
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
74. PMID: 28578601; 2017, N Engl J Med;377(6):523-533

# ACT Onco<sup>®</sup> + Report

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

75. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284  
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
76. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589  
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
77. PMID: 25366685; 2015, J Clin Oncol;33(3):244-50  
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
78. PMID: 27959613; 2016, N Engl J Med;375(20):1925-1936  
Palbociclib and Letrozole in Advanced Breast Cancer.
79. PMID: 26030518; 2015, N Engl J Med;373(3):209-19  
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
80. PMID: 28916367; 2017, Lancet;390(10106):1949-1961  
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
81. PMID: 27908594; 2017, Lancet Oncol;18(1):75-87  
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
82. PMID: 30110579; 2018, N Engl J Med;379(8):753-763  
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
83. PMID: 17538086; 2007, N Engl J Med;356(22):2271-81  
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.